Intra-Cellular Therapies to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Intra-Cellular Therapies (Nasdaq: ITCI), a biopharmaceutical company specializing in central nervous system (CNS) disorders therapeutics, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's CEO and Chairman, Sharon Mates, Ph.D., will deliver a presentation on Monday, January 13, 2025, at 11:15 a.m. PT in San Francisco.

Interested parties can access both the live and archived versions of the presentation through the 'Events & Presentations' section of the company's website at www.intracellulartherapies.com. Attendees are advised to log in 5-10 minutes before the presentation to complete registration and software installation if necessary.

BEDMINSTER, N.J., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 11:15 a.m. PT in San Francisco, CA.

The live and archived webcast can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.intracellulartherapies.com.  Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.

About Intra-Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit www.intracellulartherapies.com.

Contact:
Intra-Cellular Therapies, Inc.
Juan Sanchez, M.D.
Vice President, Corporate Communications and Investor Relations
646-440-9333

Burns McClellan, Inc.
Cameron Radinovic
cradinovic@burnsmc.com 
646-930-4406

FAQ

When is ITCI presenting at the 2025 J.P. Morgan Healthcare Conference?

Intra-Cellular Therapies (ITCI) is scheduled to present on Monday, January 13, 2025, at 11:15 a.m. PT in San Francisco.

How can investors watch ITCI's J.P. Morgan Healthcare Conference presentation?

Investors can watch the presentation through both live and archived webcasts available in the 'Events & Presentations' section of www.intracellulartherapies.com.

What is the focus area of ITCI's therapeutic development?

ITCI focuses on the development and commercialization of therapeutics for central nervous system (CNS) disorders.

Who will be presenting for ITCI at the 2025 J.P. Morgan Healthcare Conference?

Sharon Mates, Ph.D., who serves as Chief Executive Officer and Chairman of Intra-Cellular Therapies, will be presenting at the conference.